Cancer Cell Lines and Transfection

Two-dimensional (2D) and three-dimensional (3D) cell line models represent critical tools in cancer research and drug development, each offering unique advantages and limitations. These models are widely used for studying tumor biology, understanding disease mechanisms, and assessing therapeutic efficacy in both scientific research and industry applications. Their distinct structural and functional features play an essential…

Stable transfection of cancer cell lines is a foundational technique in cancer research, providing critical insights into oncogene function, cancer progression, and therapeutic responses. This method allows for the introduction and sustained expression of specific genes, such as oncogenes or tumor suppressors, into cancer cell lines, enabling a controlled investigation of their roles in tumor…

The study “Inverse-Nanoemulsion-Derived Protein Hydrogels (NanoTrans-Gels) Can Outperform DOSPA/DOPE Lipid-Complex Transfection Agent” introduces a novel class of nanomaterial-based transfection agents, NanoTrans-Gels, designed to surpass traditional lipid-based transfection methods. The authors utilized an inverse nanoemulsion method to synthesize protein hydrogels capable of encapsulating genetic material and delivering it to cancer cells with greater efficiency and stability…

Lung cancer remains one of the most common and lethal malignancies worldwide, with both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) contributing significantly to global mortality rates. The pathogenesis of lung cancer is complex, involving genetic mutations, epigenetic alterations, and environmental factors such as tobacco smoke exposure. Over the past several…

Brain cancer, particularly glioblastoma multiforme (GBM), is one of the most aggressive and lethal types of cancer, characterized by rapid growth, diffuse invasion into surrounding brain tissue, and resistance to conventional therapies such as surgery, radiation, and chemotherapy. Despite advances in molecular research and the development of novel therapeutic strategies, the prognosis for patients with…

Cancer research has made remarkable advances through the use of cancer cell lines, which have become fundamental tools for understanding tumor biology, identifying oncogenic mechanisms, and developing new therapeutic strategies. These in vitro models provide a highly controlled and reproducible environment for the study of cancer cells, making it possible to investigate the cellular and…

Kidney cancer, or renal cell carcinoma (RCC), is a malignancy originating in the renal cortex, and its study has been significantly advanced by the development and characterization of various kidney cancer cell lines. These cell lines provide invaluable models for understanding the molecular and cellular mechanisms underlying the disease, as well as for testing therapeutic…

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is one of the most aggressive and lethal malignancies, characterized by late diagnosis, rapid progression, and resistance to conventional therapies. Despite advances in the understanding of its molecular and genetic basis, the prognosis remains poor, with a five-year survival rate below 10%. The development of novel therapeutic strategies…

Liver cancer, particularly hepatocellular carcinoma (HCC), is the most common primary malignancy of the liver and the third leading cause of cancer-related deaths worldwide. Despite significant progress in the understanding of liver cancer pathogenesis, the prognosis for HCC remains poor due to its late diagnosis, high rates of recurrence, and limited therapeutic options. The development…

The study titled “Mutations of the Cx43 Gene in Non-Small Cell Lung Cancer: Association with Aberrant Localization of Cx43 Protein Expression and Tumor Progression” explores the role of connexin 43 (Cx43), a key component of gap junction intercellular communication, in the development and progression of non-small cell lung cancer (NSCLC). Connexins, including Cx43, are known…